show all | hide all No of entries

Information on EC 1.13.11.33 - arachidonate 15-lipoxygenase and Organism(s) Homo sapiens and UniProt Accession P16050

for references in articles please use BRENDA:EC1.13.11.33
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
IUBMB Comments
The product is rapidly reduced to the corresponding 15S-hydroxy compound.
Specify your search results
Select one or more organisms in this record: ?
This record set is specific for:
Homo sapiens
UNIPROT: P16050
Word Map
The taxonomic range for the selected organisms is: Homo sapiens
The enzyme appears in selected viruses and cellular organisms
Synonyms
15-lox, 15-lo-1, 15-lox-2, 15-lox2, arachidonate 15-lipoxygenase, soybean 15-lipoxygenase, 15-lipoxygenase-2, 15lo1, 15-hlo, 15-lipoxygenase 1, more
SYNONYM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
12/15 lipoxygenase
247
-
12/15-lipoxygenase
12/15-LO
12/15-LOX
247
-
12/15LO
247
-
15(S)-lipoxygenase-1
247
-
15-hLO-1
247
-
15-hLO-2
247
-
15-lipoxygenase
15-lipoxygenase 1
247
-
15-lipoxygenase 2
15-lipoxygenase type 1
283556
-
15-lipoxygenase type 2
247
-
15-lipoxygenase type-1
247
-
15-lipoxygenase-1
15-lipoxygenase-2
15-LO
15-LO-2
247
-
15-LOX
15-LOX type 1
283556
-
15-LOX-1
15-LOX-2
15-LOX-A
247
-
15-LOX2
15LO1
247
-
Alox15
ALOX15-2
247
-
ALOX15B
247
-
arachidonate 15-lipoxygenase-1
247
-
arachidonic acid 15-lipoxygenase
-
-
-
0
arachidonic acid 15-lipoxygenase-1
283556
-
endothelial 15-lipoxygenase-1
247
-
epidermis-type 15-LOX
247
-
human prostate epithelial 15-lipoxygenase-2
247
-
linoleic acid omega-6-lipoxygenase
-
-
-
0
LO-1
247
-
omega-6 lipoxygenase
-
-
-
0
oxygenase, arachidonate 15-lip-
-
-
-
0
reticulocyte 15-LOX
247
-
reticulocyte-type 15-human lipoxygenase
247
-
reticulocyte-type of 15-LOX-1
247
-
additional information
247
cf. EC 1.13.11.12
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
arachidonate + O2 = (5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
show the reaction diagram
the reaction proceeds via hydrogen abstraction, peroxide cleavage, radical rearrangement, and epoxide formation. To initiate the reaction the ferrous LOX is first activated by peroxide-dependent oxidation to a ferric form. The lipohydroperoxidase activity is initiatedwhen a lipid hydroperoxide (ROOH) is bound at the active site of the enzyme. The enzyme then catalyzes a homolytic cleavage of the hydroperoxy bond, which leads to the formation of an oxygen-centered alkoxy radical, a hydroxyl and oxidizes the ferrous iron to a ferric form. Then the enzyme binds a linoleic acid molecule (or an alterative reductant such as guaiacol) and releases a carbon-centered linoleic radical. This reaction reduces the ferric LOX back to its ferrous form to start the next catalytic cycle. The released radical intermediates may then initiate free radical secondary reactions leading to the formation of mixed oxygenated and non-oxygenated linoleic acid dimer
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
redox reaction
-
-
-
0
oxidation
-
-
-
0
reduction
-
-
-
0
dioxygenation
-
-
-
0
SYSTEMATIC NAME
IUBMB Comments
arachidonate:oxygen 15-oxidoreductase
The product is rapidly reduced to the corresponding 15S-hydroxy compound.
CAS REGISTRY NUMBER
COMMENTARY hide
82249-77-2
-
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
show the reaction diagram
arachidonate + O2
(5Z,8Z,10E,14Z)-(12S)-12-hydroperoxyicosa-5,8,10,14-tetraenoate
show the reaction diagram
-
-
-
-
?
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
show the reaction diagram
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
show the reaction diagram
arachidonate + O2
(6E,8Z,11Z,14Z)-(5S)-5-hydroperoxyicosa-6,8,11,14-tetraenoate
show the reaction diagram
-
-
-
-
?
arachidonic acid + O2
(15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid
show the reaction diagram
-
-
the mutant enzyme A416G converts arachidonic acid to (11R)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid and (15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid in a 1.5:1 ratio
-
?
arachidonic acid + O2
15S-hydroperoxy-5Z,8Z,11Z,13E-eicosatetraenoic acid
show the reaction diagram
-
-
-
-
?
arachidonic acid + O2
?
show the reaction diagram
-
-
-
-
?
eicosapentaenoic acid + O2
15-hydroxyeicosapentaenoic acid
show the reaction diagram
-
-
-
-
?
linoleate + O2
(9Z,11E)-(13S)-13-hydroperoxyoctadeca-9,11-dienoate
show the reaction diagram
-
-
-
-
?
linoleic acid + O2
(9Z,11E)-(13S)-13-hydroperoxy-octadeca-9,11-dienoate
show the reaction diagram
linoleic acid + O2
13-hydroperoxy-(9Z,11E)-linoleic acid
show the reaction diagram
-
-
-
-
?
linoleic acid + O2
13-hydroxylinoleic acid
show the reaction diagram
linoleic acid + O2
13-S-hydroxyoctadecadienoic acid
show the reaction diagram
-
both 15-LOX-1, 15-LOX-2 reacts with linoleic acid poorly
-
-
?
linoleic acid + O2
?
show the reaction diagram
lipoic acid + O2
?
show the reaction diagram
-
-
-
-
r
additional information
?
-
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
show the reaction diagram
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyeicosa-5,8,11,13-tetraenoate
show the reaction diagram
arachidonate + O2
(5Z,8Z,11Z,13E)-(15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
show the reaction diagram
-
-
-
?
linoleic acid + O2
(9Z,11E)-(13S)-13-hydroperoxy-octadeca-9,11-dienoate
show the reaction diagram
-
-
-
-
?
additional information
?
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Mg2+
-
in the presence of Mg2+, with or without calcium ionophore, the majority of 15-LO-1 is found in the membrane fraction, although significant amounts are also detected in the supernatant fraction
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
1-(3-chlorobenzoyl)-N-(2-chlorophenyl)-1H-pyrazole-3-carboxamide
-
1-acetyl-N-(3,4-dichlorophenyl)-1H-pyrazole-3-carboxamide
-
1-benzyl-N-(2-chlorophenyl)-1H-pyrazole-3-carboxamide
-
1-[(2H-1,3-benzodioxol-5-yl)carbamothioyl]-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
2-(1H-pyrazol-3-yl)-1,3-benzoxazole
-
3-(4-bromophenyl)-6-(4-chlorophenyl)-N-(2,4,4-trimethylpentan-2-yl)imidazo[2,1-b][1,3]thiazol-5-amine
-
3-(4-bromophenyl)-6-(4-chlorophenyl)-N-cyclohexylimidazo[2,1-b][1,3]thiazol-5-amine
-
3-(4-bromophenyl)-N-cyclohexyl-6-(2-nitrophenyl)imidazo[2,1-b][1,3]thiazol-5-amine
-
3-(4-methoxyphenyl)-6-phenyl-N-(2,4,4-trimethylpentan-2-yl)imidazo[2,1-b][1,3]thiazol-5-amine
protective activity of compound 5i against H2O2-induced cell death in differentiated PC12 cells
4,5-dichloro-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
4-(2-benzoylhydrazinyl)benzene-1-sulfonamide
10% inhibition
4-amino-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
4-bromo-5-chloro-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
4-bromo-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
4-butyl-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
4-chloro-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
4-chloro-N-(2-chloro-4-fluorophenyl)-5-(difluoromethyl)-1H-pyrazole-3-carboxamide
-
4-chloro-N-(2-chloro-4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazole-3-carboxamide
-
4-chlorophenyl 3-[(2-chlorophenyl)carbamoyl]-1H-pyrazole-1-carboxylate
-
4-[(E)-benzoyldiazenyl]benzene-1-sulfonamide
-
4-[(E)-benzoyldiazenyl]benzonitrile
80% inhibition, competitive
5-amino-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
5-butyl-N3-(2-chloro-4-fluorophenyl)-N1-hexyl-1H-pyrazole-1,3-dicarboxamide
-
5-chloro-2-(1H-pyrazol-3-yl)-1,3-benzoxazole
-
5-chloro-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
5-fluoro-2-(1H-pyrazol-3-yl)-1,3-benzoxazole
-
5-tert-butyl-N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
6-(2-bromophenyl)-N-cyclohexyl-3-phenylimidazo[2,1-b][1,3]thiazol-5-amine
-
6-(2-nitrophenyl)-3-phenyl-N-(2,4,4-trimethylpentan-2-yl)imidazo[2,1-b][1,3]thiazol-5-amine
-
6-(4-nitrophenyl)-3-phenyl-N-(2,4,4-trimethylpentan-2-yl)imidazo[2,1-b][1,3]thiazol-5-amine
-
6-chloro-2-(1H-pyrazol-3-yl)-1,3-benzoxazole
-
6-chloro-2-(4,5-dichloro-1H-pyrazol-3-yl)-1,3-benzoxazole
-
6-chloro-2-(5-chloro-1H-pyrazol-3-yl)-1,3-benzoxazole
-
6-fluoro-2-(1H-pyrazol-3-yl)-1,3-benzoxazole
-
baicalein
-
CDC
CAS-No. 132465-11-3
ethyl 6-([3-[(2-chloro-4-fluorophenyl)carbamoyl]-1H-pyrazole-1-carbonyl]amino)hexanoate
-
gallic acid
-
N'-(4-bromophenyl)benzohydrazide
28% inhibition
N'-(4-cyanophenyl)benzohydrazide
9% inhibition
N'-(4-methoxyphenyl)benzohydrazide
73% inhibition
N'-(4-methylphenyl)benzohydrazide
93% inhibition, competitive
N'-(4-nitrophenyl)benzohydrazide
17% inhibition
N'-phenylbenzohydrazide
33% inhibition
N-(2,4-dichlorophenyl)-1H-pyrazole-3-carboxamide
-
N-(2,5-dichlorophenyl)-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-1-(dimethylsulfamoyl)-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-1-(phenylacetyl)-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-1-methyl-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-1-[3-(trifluoromethyl)benzene-1-sulfonyl]-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-4,5-bis(trifluoromethyl)-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-4-(trifluoromethyl)-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-4-fluoro-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-4-iodo-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-4-methyl-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-4-methyl-5-(trimethylsilyl)-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-4-nitro-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-4-phenyl-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-4-[(methanesulfonyl)amino]-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-5-(difluoromethyl)-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-5-iodo-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-5-methyl-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-5-nitro-1H-pyrazole-3-carboxamide
-
N-(2-chloro-4-fluorophenyl)-5-[(methanesulfonyl)amino]-1H-pyrazole-3-carboxamide
-
N-(2-chlorophenyl)-1H-pyrazole-3-carboxamide
-
N-(2-chlorophenyl)-N-methyl-1H-pyrazole-3-carboxamide
-
N-(3,4-dichlorophenyl)-1H-pyrazole-3-carboxamide
-
N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
-
N-(5-chloro-1,3-thiazol-2-yl)-1H-pyrazole-3-carboxamide
-
N-(5-chloropyridin-2-yl)-1H-pyrazole-3-carboxamide
-
N-(5-fluoropyridin-2-yl)-1H-pyrazole-3-carboxamide
-
N-(7-fluoroquinolin-3-yl)-1H-pyrazole-3-carboxamide
-
N-(isoquinolin-3-yl)-1H-pyrazole-3-carboxamide
-
N-(pyridin-2-yl)-1H-pyrazole-3-carboxamide
-
N-(pyridin-3-yl)-1H-pyrazole-3-carboxamide
-
N-(pyridin-4-yl)-1H-pyrazole-3-carboxamide
-
N-(quinolin-2-yl)-1H-pyrazole-3-carboxamide
-
N-(quinolin-3-yl)-1H-pyrazole-3-carboxamide
-
N-(quinolin-6-yl)-1H-pyrazole-3-carboxamide
-
N-(tert-butyl)-3-phenyl-6-(p-tolyl)imidazo[2,1-b]thiazol-5-amine
-
N-(tert-butyl)-6-(4-chlorophenyl)-3-phenylimidazo[2,1-b]thiazol-5-amine
-
N-(tert-butyl)-6-(4-methoxyphenyl)-3-phenylimidazo[2,1-b]thiazol-5-amine
-
N-(tert-butyl)-6-(4-nitrophenyl)-3-phenylimidazo[2,1-b]thiazol-5-amine
-
N-benzyl-1H-pyrazole-3-carboxamide
-
N-cyclohexyl-6-(2-fluorophenyl)-3-phenylimidazo[2,1-b][1,3]thiazol-5-amine
-
N-cyclohexyl-6-(4-methoxyphenyl)-3-phenylimidazo[2,1-b][1,3]thiazol-5-amine
-
N-cyclohexyl-6-(4-nitrophenyl)-3-phenylimidazo[2,1-b][1,3]thiazol-5-amine
-
N-phenyl-1H-pyrazole-3-carboxamide
-
N-[4-(trifluoromethyl)phenyl]-1H-pyrazole-3-carboxamide
-
N-[4-fluoro-2-(trifluoromethyl)phenyl]-1H-pyrazole-3-carboxamide
-
N1-(2H-1,3-benzodioxol-5-yl)-N-3-(2-chloro-4-fluorophenyl)-1H-pyrazole-1,3-dicarboxamide
-
N1-butyl-N3-(2-chlorophenyl)-N3-methyl-1H-pyrazole-1,3-dicarboxamide
-
N3-(2,2-difluoro-2H-1,3-benzodioxol-4-yl)-N1-hexyl-5-methyl-1H-pyrazole-1,3-dicarboxamide
-
N3-(2-chloro-4-fluorophenyl)-N1-hexyl-4-methyl-1H-pyrazole-1,3-dicarboxamide
-
N3-(2-chloro-4-fluorophenyl)-N1-pentyl-1H-pyrazole-1,3-dicarboxamide
-
N3-(2-chlorophenyl)-N1,N1-dimethyl-1H-pyrazole-1,3-dicarboxamide
-
nordihydroguaiaretic acid
-
phenyl[(E)-phenyldiazenyl]methanone
87% inhibition
quercetin
-
[(E)-(4-bromophenyl)diazenyl](phenyl)methanone
44% inhibition
[(E)-(4-methoxyphenyl)diazenyl](phenyl)methanone
19% inhibition
[(E)-(4-methylphenyl)diazenyl](phenyl)methanone
44% inhibition
[(E)-(4-nitrophenyl)diazenyl](phenyl)methanone
34% inhibition
(Z)-9-octadecenyl sulfate
-
allosteric inhibition
11-thialinoleic acid
-
is a noncompetitive inhibitor of 15-lipoxygenase-1 with respect to arachidonate or linoleic acid as substrates. Presence of inhibitor does not alter the product distribution for 15-lipoxygenase-1. It does not change the regioselectivity of 15-lipoxygenase-1
2,3,4,5-tetrabromo-6-(2,4-dibromophenoxy)phenol
-
IC50: 0.0018 mM
2,3,4,5-tetrabromo-6-(3,5-dibromo-2-hydroxyphenoxy)phenol
-
IC50: 0.00079 mM
2,3,5-tribromo-6-(3,5-dibromo-2-hydroxyphenoxy)phenol
-
IC50: 0.0022 mM
2,4-dibromo-6-(2,4-dibromo-6-methoxyphenoxy)phenol
-
IC50: 0.01 mM
2,4-Dibromophenol
-
IC50: 0.034 mM
2,6-dibromo-4-[1-(3-bromo-4-hydroxyphenyl)-1-methylethyl]phenol
-
IC50: 0.005 mM
2-([4-[(4-fluorobenzyl)oxy]butyl]sulfanyl)-5-(naphthalen-1-yl)-1,3,4-oxadiazole
-
-
2-alkyl benzopyran-4-ones
-
weak inhibition of isozymes 15-hLO-1 and 15-hLO-2
2-alkyl-6-hydroxy-4-H-benzopyran-4-one
-
weak inhibition of isozymes 15-hLO-1 and 15-hLO-2
3'-chloro-7,8-dihydroxyisoflavone
-
weak inhibition of isozyme 15-hLO-2
3,4,6,8-tetrabromooxanthren-1-ol
-
IC50: 0.0009 mM
3,4,6-tribromo-2-(2,4-dibromophenoxy)phenol
-
IC50: 0.005 mM
3,4-dibromo-2-(5-bromo-2-hydroxyphenoxy)phenol
-
IC50: 0.011 mM
3,6,8-tribromooxanthren-1-ol
-
IC50: 0.0008 mM
3-hydroxy-H-benzopyran-4-one derivatives
-
weak inhibition of isozymes 15-hLO-1 and 15-hLO-2
3-[3-bromo-5-(2,6-dibromo-4-{2-[2-(3-bromo-4-hydroxy-phenyl)-ethylcarbamoyl]-2-[(E)-hydroxyimino]-ethyl}-phenoxy)-4-methyl-phenyl]-N-[(E)-2-(3,5-dibromo-4-hydroxy-phenyl)-vinyl]-2-[(E)-hydroxyimino]-propionamide
-
IC50: 0.059 mM
4',6,7-trihydroxyisoflavan
-
-
4',6,7-trihydroxyisoflavanone
-
weak inhibition of isozyme 15-hLO-2
4',6,7-trihydroxyisoflavone
-
weak inhibition of isozyme 15-hLO-2
4'-chloro-7,8-dihydroxyisoflavone
-
weak inhibition of isozyme 15-hLO-2
4,4'-propane-2,2-diylbis(2,6-dibromophenol)
-
IC50: 0.004 mM
4-((5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)butyl)-4-fluorobenzoate
-
-
4-((5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)methyl)-benzyl-4-fluorobenzoate
-
-
4-(2-chlorophenyl)-N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide
-
-
4-(3,4-dichlorophenyl)-N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide
-
-
4-(3,4-dichlorophenyl)-N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide
-
-
4-(5-(1H-indol-2-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-(5-(2-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-(5-(2-fluorophenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-(5-(2-methoxyphenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-(5-(3-fluorophenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-(5-(3-hydroxynaphthalen-2-yl)-1,3,4-oxadiazol-2-ylthio)-but-2-ynyl-4-fluorobenzoate
-
low solubility
4-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-(5-(4-fluorophenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-(5-(furan-2-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylamino)but-2-ynyl-thiophene-2-carboxylate
-
-
4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)but-2-yn-1-ol
-
-
4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-1H-indole-4-carboxylate
-
-
4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-benzofuran-2-carboxylate
-
-
4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-thiophene-2-carboxylate
-
-
4-(5-(naphthalen-1-yl)-1,3,4-thiadiazol-2-ylthio)but-2-ynyl-thiophene-2-carboxylate
-
low solubility
4-(5-(quinolin-5-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-(5-(thiophen-2-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-(5-phenyl-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
-
4-allyl-2-methoxyphenyl 1-adamantanecarboxylate
-
-
4-allyl-2-methoxyphenyl 1-cyclohexanecarboxylate
-
-
4-allyl-2-methoxyphenyl 2-chlorobenzoate
-
-
4-allyl-2-methoxyphenyl 2-fluorobenzoate
-
-
4-allyl-2-methoxyphenyl 2-methylbenzoate
-
-
4-allyl-2-methoxyphenyl 2-pyridinecarboxylate
-
-
4-allyl-2-methoxyphenyl 3-chlorobenzoate
-
-
4-allyl-2-methoxyphenyl 3-fluorobenzoate
-
-
4-allyl-2-methoxyphenyl 3-methoxybenzoate
-
-
4-allyl-2-methoxyphenyl 3-methylbenzoate
-
-
4-allyl-2-methoxyphenyl 4-chlorobenzoate
-
-
4-allyl-2-methoxyphenyl 4-fluorobenzoate
-
-
4-allyl-2-methoxyphenyl 4-methoxybenzoate
-
-
4-allyl-2-methoxyphenyl 4-methylbenzoate
-
-
4-allyl-2-methoxyphenyl benzoate
-
-
4-allyl-2-methoxyphenyl isonicotinate
-
-
4-allyl-2-methoxyphenyl nicotinate
-
-
4-Bromophenol
-
IC50: 0.055 mM
4-butyl-N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide
-
-
4-pentyl-N-(2-[2-phenyl-5-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]ethyl)benzenesulfonamide
-
-
4-pentyl-N-[2-(5-phenyl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
-
-
4-pentyl-N-[2-(5-phenyl-2-pyrazin-2-yl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
-
-
4-pentyl-N-[2-(5-phenyl-2-pyridin-2-yl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
-
-
4-pentyl-N-[2-(5-phenyl-2-pyridin-3-yl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
-
-
4-pentyl-N-[2-(5-phenyl-2-pyridin-4-yl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
-
-
4-pentyl-N-[2-(5-phenyl-2-thioformyl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
-
-
4-pentyl-N-[3-(5-phenyl-2-thioformyl-1H-imidazol-4-yl)propyl]benzenesulfonamide
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 1-benzothiophene-2-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 1-benzothiophene-3-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 1H-imidazole-4-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 2,4-difluorobenzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 2-fluorobenzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 2-fluoropyridine-3-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 2-methoxybenzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3,4,5-trichlorothiophene-2-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3,4,5-trifluorobenzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3,4-difluorobenzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3-(trifluoromethyl)benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3-chloro-1-benzothiophene-2-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3-chlorothiophene-2-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3-fluorobenzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(difluoromethoxy)benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(methylsulfonyl)benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(triazan-2-yl)benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(trifluoromethoxy)benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(trifluoromethyl)benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-bromobenzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-chloro-3-(trifluoromethyl)benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-[(trifluoromethyl)sulfanyl]benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl benzoate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl cyclobutanecarboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl cyclopentanecarboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl cyclopropanecarboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl furan-2-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl naphthalene-2-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl thiophene-3-carboxylate
-
-
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]butyl 4-fluorobenzoate
-
-
4-[[5-(naphthalen-2-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-fluorobenzoate
-
-
4-{[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl}but-2-yn-1-yl 4-chlorobenzoate
-
-
4-{[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl}but-2-yn-1-yl 4-fluorobenzoate
-
-
4-{[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl}but-2-yn-1-yl 4-methoxybenzoate
-
-
5,8,11,14-Eicosatetraynoic acid
6,11-dihydro[1]benzothiopyrano[4,3-b]indole
-
PD146176
6,7-dihydroxy-2-t-butylbenzopyran-4-one
-
weak inhibition of isozyme 15-hLO-2
6,7-dihydroxy-3',4'-methylenedioxyisoflavan
-
-
6,7-dihydroxy-3'-methylisoflavan
-
-
6,7-dihydroxy-3'-methylisoflavanone
-
weak inhibition of isozyme 15-hLO-2
6,7-dihydroxy-4'-methoxyisoflavan
-
-
6,7-dihydroxy-4'-methoxyisoflavanone
-
weak inhibition of isozyme 15-hLO-2
6,7-dihydroxyisoflavones
-
weak inhibition of isozymes 15-hLO-1 and 15-hLO-2
6-hydroxy-2-pentyl-4H-benzopyran-4-one
-
weak inhibition of isozyme 15-hLO-2
6-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]-1-phenylhexan-1-one
-
low solubility
7,8-dihydroxy-3',4'-dimethoxyisoflavan
-
-
7,8-dihydroxy-3'-methylisoflavone
-
weak inhibition of isozyme 15-hLO-2
7,8-dihydroxy-3'-trifluoromethylisoflavone
-
weak inhibition of isozyme 15-hLO-2
7,8-dihydroxy-4'-methoxyisoflavan
-
-
7,8-dihydroxy-4'-methylisoflavan
-
-
7,8-dihydroxy-4'-methylisoflavone
-
weak inhibition of isozyme 15-hLO-2
7,8-dihydroxyisoflavone
-
weak inhibition of isozyme 15-hLO-2
7-hydroxy-H-benzopyran-4-one derivatives
-
weak inhibition of isozymes 15-hLO-1 and 15-hLO-2
alpha-mangostin
-
NSC30552, a natural product, caspase-3 pathway inhibitor, performs selective inhibition of 12-LO
anthraquinone
-
-
apigenin
-
IC50: 0.0034 mM without Triton X-100, IC50: 0.0003 mM in the presence of 0.01% Triton X-100
arachidonic acid
-
autoinactivates 15-hLO-1 to a much greater extent than linoleic acid at high substrate concentrations. No autoinactivation at low substrate concentrations
baicalein
bestatin 7
-
IC50: 0.027 mM
caffeic acid
cinnamyl 3,4-dihydroxy-cyanocinnamate
-
CDC
conjugated linoleic acids
-
conjugated linoleic acids may function as inhibitors of 15-LO-1 activity in macrophages/in vivo, overview
-
dysidenin
-
-
eicosatetraynoic acid
-
-
esculetin
-
-
GATA-6
-
inhibits non-steroidal anti-inflammatory drugs-induced transcription of 15-LOX-1 in colorectal cancer cells
-
glucocorticoid
-
inhibits induction in monocytes
-
interferon-gamma
-
inhibits induction in monocytes
-
linoleic acid
michellamine B
-
NSC661755, potent but non-selective inhibitor, a natural anti-viral agent
N'-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N-methyl-N-[(3R)-1-phenoxypyrrolidin-3-yl]sulfamide
-
-
N'-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N-methyl-N-[(3S)-1-phenoxypyrrolidin-3-yl]sulfamide
-
-
N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-N-methyl-N-[(3R)-1-phenoxypyrrolidin-3-yl]sulfamide
-
-
N-(4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol)-2-ylthio)but-2-ynyl-thiophene-2-carboxamide
-
-
N-ethyl-N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-N-[(3R)-1-(1-methyl-1-phenylethyl)pyrrolidin-3-yl]sulfamide
-
-
N-ethyl-N-[(3R)-1-[1-(4-fluorophenyl)ethyl]pyrrolidin-3-yl]-N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]sulfamide
-
-
N-[(3R)-1-(3,4-dichlorobenzyl)pyrrolidin-3-yl]-N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-N-methylsulfamide
-
-
N-[2-(2,5-diphenyl-1H-imidazol-4-yl)ethyl]-4-methylbenzenesulfonamide
-
-
N-[2-(2,5-diphenyl-1H-imidazol-4-yl)ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-(2-cyclopropyl-5-phenyl-1H-imidazol-4-yl)ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-(2-methyl-5-phenyl-1H-imidazol-4-yl)ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-(2-tert-butyl-5-phenyl-1H-imidazol-4-yl)ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(2-methyl-1,3-thiazol-4-yl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(3-nitrophenyl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(4-chlorophenyl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(4-methoxyphenyl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[2-(4-methylphenyl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[5-(3-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[5-(4-fluorophenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
-
-
N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-phenylpiperazine-1-sulfonamide
-
-
N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N'-[(3R)-1-phenoxypyrrolidin-3-yl]sulfamide
-
-
N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N'-[(3S)-1-phenoxypyrrolidin-3-yl]sulfamide
-
-
N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-4-pentylpiperazine-1-sulfonamide
-
-
N-[3-(2,5-diphenyl-1H-imidazol-4-yl)propyl]-4-pentylbenzenesulfonamide
-
-
neodysidenin
-
natural product from marine sponge Dysidea herbacea from Papua New Guinea, extraction and purification, overview, steady-state inhibition kinetics, competitive mode of inhibition, selective for 12-LO
nor-dihydro-guaiaretic acid
-
-
nordihydroguaiaretic acid
NSC172033
-
a synthetic compound from the NCI library
NSC292213
-
a synthetic compound from the NCI library
NSC617570
-
a synthetic compound from the NCI library
PD146176
-
-
quercetin
-
-
siRNA
-
additional information
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
12(S)-hydroperoxyeicosatetraenoic acid
-
reduces the kinetic lag phase
13(S)-hydroperoxyoctadecadienoic acid
-
activates 15-hLO-1 and removes the kinetic lag phase
13-(S)-hydroxyoctadecadienoic acid
-
allosteric effector, which changes the conformation of 15-hLO-2 such that substrate affinity toward linoleic acid is significantly increased
13-hydroperoxy-octadecadienoic acid
-
-
15(S)-hydroperoxyeicosatetraenoic acid
-
activates 15-hLO-1 and removes the kinetic lag phase
Acetylsalicylic acid
-
ASA, 40% activation of 15(S)-HETE production at 0.02 mM in ASA-sensitive asthmatic patients
mannitol
-
osmotic activation of nasal tissue with mannitol activates 15-LO-1 leading to increased amounts of 15(S)-hydroxyeicosatetranoic acid in nasal lavage, and the levels of 15(S)-hydroxyeicosatetranoic acid are associated with nasal symptoms
phosphatidylcholine
-
stimulates
phosphatidylinositol-3,4-bisphosphate
-
0.02 mM, 3fold activity increase, in the presence of Ca2+
phosphatidylinositol-4,5-bisphosphate
-
0.02 mM, 3fold activity increase, in the presence of Ca2+
additional information
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.005
arachidonate
-
-
0.0025 - 1.1
arachidonic acid
0.003 - 0.0772
linoleic acid
0.01
lipoic acid
-
splice variant 15-LOb1
0.0096 - 4.2
O2
additional information
additional information
-
steady-state kinetics of isozymes 15-hLO-1 and 15-hLO-2 with arachidonate and linoleic acid in presence or absence of 0.2% sodium cholate, or of oxygenated fatty acids, overview
-
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
3 - 14
arachidonate
0.57 - 9.93
arachidonic acid
4 - 17.8
linoleic acid
5.1 - 7.6
O2
kcat/KM VALUE [1/mMs-1]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00005 - 0.00075
arachidonic acid
240 - 790
O2
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00398
4-[(E)-benzoyldiazenyl]benzonitrile
pH and temperature not specified in the publication
0.00081
N'-(4-methylphenyl)benzohydrazide
pH and temperature not specified in the publication
0.1
2-([4-[(4-fluorobenzyl)oxy]butyl]sulfanyl)-5-(naphthalen-1-yl)-1,3,4-oxadiazole
-
Ki above 0.1 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.0006
4-((5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)butyl)-4-fluorobenzoate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.07
4-((5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)methyl)-benzyl-4-fluorobenzoate
-
apparent value, Ki above 0.07 mM, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000023
4-(5-(1H-indol-2-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000057
4-(5-(2-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000043
4-(5-(2-fluorophenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000081
4-(5-(2-methoxyphenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-(5-(3-fluorophenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
apparent value, Ki above 0.00001 mM, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
apparent value, Ki above 0.00001 mM, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-(5-(4-fluorophenyl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
apparent value, Ki above 0.00001 mM, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.001
4-(5-(furan-2-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.0013
4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylamino)but-2-ynyl-thiophene-2-carboxylate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.0035
4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)but-2-yn-1-ol
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000076
4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-1H-indole-4-carboxylate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000015
4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-benzofuran-2-carboxylate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000019
4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-thiophene-2-carboxylate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00014
4-(5-(quinolin-5-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000082
4-(5-(thiophen-2-yl)-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000026
4-(5-phenyl-1,3,4-oxadiazol-2-ylthio)but-2-ynyl-4-fluorobenzoate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 1-benzothiophene-2-carboxylate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 1-benzothiophene-3-carboxylate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.0014
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 1H-imidazole-4-carboxylate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 2,4-difluorobenzoate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 2-fluorobenzoate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 2-fluoropyridine-3-carboxylate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00047
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 2-methoxybenzoate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3,4,5-trichlorothiophene-2-carboxylate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000016
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3,4,5-trifluorobenzoate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3,4-difluorobenzoate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000027
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3-(trifluoromethyl)benzoate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000031
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3-chloro-1-benzothiophene-2-carboxylate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3-chlorothiophene-2-carboxylate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 3-fluorobenzoate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(difluoromethoxy)benzoate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000033
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(methylsulfonyl)benzoate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000015
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(triazan-2-yl)benzoate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(trifluoromethoxy)benzoate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-(trifluoromethyl)benzoate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-bromobenzoate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.0001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-chloro-3-(trifluoromethyl)benzoate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-[(trifluoromethyl)sulfanyl]benzoate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl benzoate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000085
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl cyclobutanecarboxylate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl cyclopentanecarboxylate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00027
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl cyclopropanecarboxylate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00017
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl furan-2-carboxylate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000022
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl naphthalene-2-carboxylate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl thiophene-3-carboxylate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.000026
4-[[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]butyl 4-fluorobenzoate
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-[[5-(naphthalen-2-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]but-2-yn-1-yl 4-fluorobenzoate
-
Ki less than 0.00001 mM, apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-{[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl}but-2-yn-1-yl 4-chlorobenzoate
-
apparent value, Ki above 0.00001 mM, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-{[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl}but-2-yn-1-yl 4-fluorobenzoate
-
apparent value, Ki above 0.00001 mM, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.00001
4-{[5-(naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]sulfanyl}but-2-yn-1-yl 4-methoxybenzoate
-
apparent value, Ki above 0.00001 mM, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.002
apigenin
-
-
0.00018 - 0.0011
baicalein
0.008
dysidenin
-
above, pH 7.5, recombinant isozyme 15-hLO-1
0.005 - 0.017
linoleic acid
0.002
N-(4-(5-(naphthalen-1-yl)-1,3,4-oxadiazol)-2-ylthio)but-2-ynyl-thiophene-2-carboxamide
-
apparent value, in 25 mM HEPES buffer (pH 7.5), 0.01% (v/v) Triton X-100, at 23°C
0.5
neodysidenin
-
above, pH 7.5, recombinant isozyme 15-hLO-1
additional information
additional information
-
-
-
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00978
4-[(E)-benzoyldiazenyl]benzonitrile
Homo sapiens
pH and temperature not specified in the publication
0.00535
N'-(4-methylphenyl)benzohydrazide
Homo sapiens
pH and temperature not specified in the publication
0.00697
phenyl[(E)-phenyldiazenyl]methanone
Homo sapiens
pH and temperature not specified in the publication
0.0018
2,3,4,5-tetrabromo-6-(2,4-dibromophenoxy)phenol
Homo sapiens
-
IC50: 0.0018 mM
0.00079
2,3,4,5-tetrabromo-6-(3,5-dibromo-2-hydroxyphenoxy)phenol
Homo sapiens
-
IC50: 0.00079 mM
0.0022
2,3,5-tribromo-6-(3,5-dibromo-2-hydroxyphenoxy)phenol
Homo sapiens
-
IC50: 0.0022 mM
0.01
2,4-dibromo-6-(2,4-dibromo-6-methoxyphenoxy)phenol
Homo sapiens
-
IC50: 0.01 mM
0.034
2,4-Dibromophenol
Homo sapiens
-
IC50: 0.034 mM
0.005
2,6-dibromo-4-[1-(3-bromo-4-hydroxyphenyl)-1-methylethyl]phenol
Homo sapiens
-
IC50: 0.005 mM
0.0062
3'-chloro-7,8-dihydroxyisoflavone
Homo sapiens
-
pH 7.5, 22°C, isozyme 15-hLO-1
0.0009
3,4,6,8-tetrabromooxanthren-1-ol
Homo sapiens
-
IC50: 0.0009 mM
0.005
3,4,6-tribromo-2-(2,4-dibromophenoxy)phenol
Homo sapiens
-
IC50: 0.005 mM
0.011
3,4-dibromo-2-(5-bromo-2-hydroxyphenoxy)phenol
Homo sapiens
-
IC50: 0.011 mM
0.0008
3,6,8-tribromooxanthren-1-ol
Homo sapiens
-
IC50: 0.0008 mM
0.059
3-[3-bromo-5-(2,6-dibromo-4-{2-[2-(3-bromo-4-hydroxy-phenyl)-ethylcarbamoyl]-2-[(E)-hydroxyimino]-ethyl}-phenoxy)-4-methyl-phenyl]-N-[(E)-2-(3,5-dibromo-4-hydroxy-phenyl)-vinyl]-2-[(E)-hydroxyimino]-propionamide
Homo sapiens
-
IC50: 0.059 mM
0.00051 - 0.071
4',6,7-trihydroxyisoflavan
0.0038 - 0.1
4',6,7-trihydroxyisoflavanone
0.049
4',6,7-trihydroxyisoflavone
Homo sapiens
-
pH 7.5, 22°C, isozyme 15-hLO-1
0.009
4'-chloro-7,8-dihydroxyisoflavone
Homo sapiens
-
pH 7.5, 22°C, isozyme 15-hLO-1
0.004
4,4'-propane-2,2-diylbis(2,6-dibromophenol)
Homo sapiens
-
IC50: 0.004 mM
0.045 - 0.132
4-(2-chlorophenyl)-N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide
0.055 - 0.378
4-(3,4-dichlorophenyl)-N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide
0.036 - 0.133
4-(3,4-dichlorophenyl)-N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide
0.055
4-Bromophenol
Homo sapiens
-
IC50: 0.055 mM
0.014 - 0.05
4-butyl-N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]piperazine-1-sulfonamide
0.000072 - 0.000372
4-pentyl-N-(2-[2-phenyl-5-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl]ethyl)benzenesulfonamide
0.01
4-pentyl-N-[2-(5-phenyl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
Homo sapiens
-
above, versus substrate linoleic acid
0.00281
4-pentyl-N-[2-(5-phenyl-2-pyrazin-2-yl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
Homo sapiens
-
versus substrate linoleic acid
0.00097 - 5.321
4-pentyl-N-[2-(5-phenyl-2-pyridin-2-yl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
0.00056
4-pentyl-N-[2-(5-phenyl-2-pyridin-3-yl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
Homo sapiens
-
versus substrate linoleic acid
0.000087 - 3.211
4-pentyl-N-[2-(5-phenyl-2-pyridin-4-yl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
0.000006 - 0.000013
4-pentyl-N-[2-(5-phenyl-2-thioformyl-1H-imidazol-4-yl)ethyl]benzenesulfonamide
0.000053 - 0.000396
4-pentyl-N-[3-(5-phenyl-2-thioformyl-1H-imidazol-4-yl)propyl]benzenesulfonamide
0.018
6,7-dihydroxy-2-t-butylbenzopyran-4-one
Homo sapiens
-
pH 7.5, 22°C, isozyme 15-hLO-1
0.00035 - 0.016
6,7-dihydroxy-3',4'-methylenedioxyisoflavan
0.00021 - 0.0083
6,7-dihydroxy-3'-methylisoflavan
0.00021 - 0.014
6,7-dihydroxy-3'-methylisoflavanone
0.00015 - 0.1
6,7-dihydroxy-4'-methoxyisoflavan
0.0016 - 0.019
6,7-dihydroxy-4'-methoxyisoflavanone
0.038
6-hydroxy-2-pentyl-4H-benzopyran-4-one
Homo sapiens
-
pH 7.5, 22°C, isozyme 15-hLO-1
0.1
7,8-dihydroxy-3',4'-dimethoxyisoflavan
0.011
7,8-dihydroxy-3'-methylisoflavone
Homo sapiens
-
pH 7.5, 22°C, isozyme 15-hLO-1
0.0083
7,8-dihydroxy-3'-trifluoromethylisoflavone
Homo sapiens
-
pH 7.5, 22°C, isozyme 15-hLO-1
0.0037 - 0.1
7,8-dihydroxy-4'-methoxyisoflavan
0.0057 - 0.1
7,8-dihydroxy-4'-methylisoflavan
0.0078
7,8-dihydroxy-4'-methylisoflavone
Homo sapiens
-
pH 7.5, 22°C, isozyme 15-hLO-1
0.013
7,8-dihydroxyisoflavone
Homo sapiens
-
pH 7.5, 22°C, isozyme 15-hLO-1
0.0031 - 0.05
alpha-mangostin
0.0003 - 100
apigenin
Homo sapiens
-
IC50: 0.0034 mM without Triton X-100, IC50: 0.0003 mM in the presence of 0.01% Triton X-100
0.038 - 100
baicalein
Homo sapiens
-
potent inhibitor, IC50: 0.0016 mM without Triton X-100, IC50: 0.038 mM in the presence of 0.01% Triton X-100
0.027
bestatin 7
Homo sapiens
-
IC50: 0.027 mM
0.0076 - 0.05
michellamine B
0.031 - 0.186
N'-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N-methyl-N-[(3R)-1-phenoxypyrrolidin-3-yl]sulfamide
0.08 - 0.822
N'-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N-methyl-N-[(3S)-1-phenoxypyrrolidin-3-yl]sulfamide
0.038 - 0.375
N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-N-methyl-N-[(3R)-1-phenoxypyrrolidin-3-yl]sulfamide
0.01 - 0.132
N-ethyl-N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-N-[(3R)-1-(1-methyl-1-phenylethyl)pyrrolidin-3-yl]sulfamide
0.003 - 0.75
N-ethyl-N-[(3R)-1-[1-(4-fluorophenyl)ethyl]pyrrolidin-3-yl]-N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]sulfamide
0.011 - 0.083
N-[(3R)-1-(3,4-dichlorobenzyl)pyrrolidin-3-yl]-N'-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-N-methylsulfamide
0.000364 - 0.0028
N-[2-(2,5-diphenyl-1H-imidazol-4-yl)ethyl]-4-methylbenzenesulfonamide
0.000033 - 0.000162
N-[2-(2,5-diphenyl-1H-imidazol-4-yl)ethyl]-4-pentylbenzenesulfonamide
0.01
N-[2-(2-cyclopropyl-5-phenyl-1H-imidazol-4-yl)ethyl]-4-pentylbenzenesulfonamide
0.01
N-[2-(2-methyl-5-phenyl-1H-imidazol-4-yl)ethyl]-4-pentylbenzenesulfonamide
Homo sapiens
-
above, versus substrate linoleic acid
0.00192 - 0.01
N-[2-(2-tert-butyl-5-phenyl-1H-imidazol-4-yl)ethyl]-4-pentylbenzenesulfonamide
0.00072
N-[2-[2-(2-methyl-1,3-thiazol-4-yl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
Homo sapiens
-
versus substrate linoleic acid
0.000099 - 0.0011
N-[2-[2-(3-nitrophenyl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
0.000021 - 0.0011
N-[2-[2-(4-chlorophenyl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
0.01
N-[2-[2-(4-methoxyphenyl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
Homo sapiens
-
above, versus substrate linoleic acid
0.003
N-[2-[2-(4-methylphenyl)-5-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
Homo sapiens
-
versus substrate linoleic acid
0.000082 - 0.000531
N-[2-[5-(3-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
0.000059 - 0.000261
N-[2-[5-(4-fluorophenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
0.000014 - 0.00005
N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-pentylbenzenesulfonamide
0.212 - 3.45
N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-4-phenylpiperazine-1-sulfonamide
0.083 - 0.719
N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N'-[(3R)-1-phenoxypyrrolidin-3-yl]sulfamide
0.272 - 2.41
N-[2-[5-(4-methoxyphenyl)-2-phenyl-1H-imidazol-4-yl]ethyl]-N'-[(3S)-1-phenoxypyrrolidin-3-yl]sulfamide
0.091 - 0.646
N-[2-[5-(4-methoxyphenyl)-2-thioformyl-1H-imidazol-4-yl]ethyl]-4-pentylpiperazine-1-sulfonamide
0.00014 - 0.000914
N-[3-(2,5-diphenyl-1H-imidazol-4-yl)propyl]-4-pentylbenzenesulfonamide
0.5
neodysidenin
Homo sapiens
-
above, pH 7.5, recombinant isozyme 15-hLO-1
0.00011
nordihydroguaiaretic acid
Homo sapiens
-
IC50: 0.00011 mM
0.0094 - 0.05
NSC172033
0.025 - 0.05
NSC292213
0.05 - 0.5
NSC617570
0.1
additional information
Homo sapiens
-
IC50 above 0.1 mM: compound 1a, compound 1b, compound 1d, compound 1e, compound 1g
-
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
2.125
-
-
additional information
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
6.7 - 7.3
-
-
6.8 - 7.2
-
-
7 - 8.5
-
-
8 - 9
-
pH-optimum of 15-LOX-2 for arachidonic acid oxygenation
pH RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
6 - 9.5
-
pH 6 about 50% of maximal activity, pH 9.5 about 60% of maximal activity
7 - 8
-
approximately level between pH 7 and 8
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
visceral adipose tissue
Manually annotated by BRENDA team
-
epidermoid carcinoma of the submandibular gland
Manually annotated by BRENDA team
-
expression, but no activity of 15-LOX in leukemic blasts induced by a Ca2+ ionophore, from acute myeloid leukemic and acute lymphoid leukemic patients, overview, quantitative expression analysis
Manually annotated by BRENDA team
-
medium expression
Manually annotated by BRENDA team
-
breast carcinoma BT-20 cells
Manually annotated by BRENDA team
-
express both 15-LOX-1 and -2
Manually annotated by BRENDA team
-
15-LOX-1 but not 15-LOX-2
Manually annotated by BRENDA team
-
hypopharyngeal carcinoma
Manually annotated by BRENDA team
-
epidermal carcinoma of the mouth
Manually annotated by BRENDA team
-
carcinoma of the retromolar trigone region
Manually annotated by BRENDA team
-
higher expression of 15-LO-1 compared with ostheoarthritis synovial tissue
Manually annotated by BRENDA team
-
15-LOX-1 and 15-LOX-2
Manually annotated by BRENDA team
-
CD14+
Manually annotated by BRENDA team
-
squamous cell carcinoma of retromolar trigone
Manually annotated by BRENDA team
-
laryngeal carcinoma
Manually annotated by BRENDA team
-
squamous cell carcinoma of floor mouth
Manually annotated by BRENDA team
additional information